» Articles » PMID: 38450290

Basics and Art of Immunosuppression in Liver Transplantation

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2024 Mar 7
PMID 38450290
Authors
Affiliations
Soon will be listed here.
Abstract

Liver transplantation is one of the most challenging areas in the medical field. Despite that, it has already been established as a standard treatment option, especially in decompensated cirrhosis and selected cases of hepatocellular carcinoma and acute liver failure. Complications due to graft rejection, including mortality and morbidity, have greatly improved over time due to better immunosuppressive agents and management protocols. Currently, immunosuppression in liver transplant patients makes use of the best possible combinations of effective agents to achieve optimal immunosuppression for long-term graft survival. Induction agents are no longer used routinely, and the aim is to provide minimal immunosuppression in the maintenance phase. Currently available immunosuppressive agents are mainly classified as biological and pharmacological agents. Though the protocols may vary among the centers and over time, the basics of effective use usually remain similar. Most protocols use the combination of multiple agents with different mechanisms of action to reduce the dose and minimize the side effects. Along with the improvement in operative and perioperative techniques, this art of immunosuppression has contributed to the recent progress made in the outcomes of liver transplants. In this review, we will discuss the various types of immunosuppressive agents currently in use, the different protocols of immunosuppression used, and the art of optimal use for achieving maximum immunosuppression without increasing toxicity. We will also discuss the practical aspects of various immunosuppression regimens, including drug monitoring, and briefly discuss the concepts of immunosuppression minimization and withdrawal.

Citing Articles

Efficacy of Engraftment and Safety of Human Umbilical Di-Chimeric Cell (HUDC) Therapy after Systemic Intraosseous Administration in an Experimental Model.

Siemionow M, Chambily L, Brodowska S Biomedicines. 2024; 12(5).

PMID: 38791026 PMC: 11117770. DOI: 10.3390/biomedicines12051064.

References
1.
Charlton M, Levitsky J, Aqel B, OGrady J, Hemibach J, Rinella M . International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018; 102(5):727-743. DOI: 10.1097/TP.0000000000002147. View

2.
Zhang G, Zhang C, Sun N, Lv W, Chen B, Zhang J . Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials. Hepatobiliary Pancreat Dis Int. 2017; 16(2):139-146. DOI: 10.1016/s1499-3872(16)60183-2. View

3.
Ritter M, Pirofski L . Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009; 11(4):290-7. PMC: 2852585. DOI: 10.1111/j.1399-3062.2009.00407.x. View

4.
Nakamura K, Tanaka T, Masumori N, Miyamoto A, Hirano T . Evaluation of Proteinuria Using Urine Protein : Creatine Ratio in Treatment with Molecular Targeted Agents for Advanced Renal Cell Carcinoma. Biol Pharm Bull. 2020; 43(10):1506-1510. DOI: 10.1248/bpb.b20-00256. View

5.
Krishnamoorthy T, Miezynska-Kurtycz J, Hodson J, Gunson B, Neuberger J, Milkiewicz P . Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. Liver Transpl. 2015; 22(1):34-41. DOI: 10.1002/lt.24323. View